A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer

Lung Cancer

Volumn 45, Issue 1, 2004, Pages 77-84

  Hotta, Katsuyuki ^a   Ueoka, Hiroshi ^a   Kiura, Katsuyuki ^a   Tabata, Masahiro ^a   Kuyama, Shoichi ^a   Satoh, Ken ^a   Kozuki, Toshiyuki ^a   Hisamoto, Akiko ^a   Hosokawa, Shinobu ^a   Fujiwara, Keiichi ^a   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Irinotecan; Non platinum regimen; Non small cell lung cancer; Paclitaxel; Pharmacokinetics; Phase I study

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; DIGOXIN; DIPHENHYDRAMINE; IRINOTECAN; PACLITAXEL; RANITIDINE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPONATREMIA; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; MYALGIA; NAUSEA; NEUTROPENIA; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL;

EID: 2942519332     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.01.001     Document Type: Article

References (23)

1. Stanley K., Stjernswa R.D.J. Lung cancer - a worldwide health problem. Chest. 96:1989;S1-S5
2. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995;311:899-909.
3. Hotta K., Sekine I., Tamura T., Sawada M., Watanabe H., Kusaba H., et al. A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer. Jpn. J. Clin. Oncol. 31:2001;596-600
4. Negoro S., Masuda N., Takada Y., Sugiura T., Kudoh S., Katakami N., et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br. J. Cancer. 88:2003;335
5. Hainsworth J.D., Thompson D.S., Greco F.A. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J. Clin. Oncol. 3:1995;1609-1614
6. Ranson M., Davidson N., Nicolson M., Falk S., Carmichael J., Lopez P., et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 92:2000;1074-1080
7. Pei X.H., Nakanishi Y., Takayama K., Bai F., Kawasaki M., Tsuruta N., et al. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells. Anticancer Drugs. 8:1997;231-237
8. Kasai T., Oka M., Soda H., Tsurutani J., Fukuda M., Nakamura Y., et al. Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small cell lung cancer. Eur. J. Cancer. 38:2002;1871-1878
9. Yamamoto N, Negoro S, Chikazawa H, Shimizu T, Fukuoka M. Pharmacokinetic interaction of the combination of paclitaxel and irinotecan in vivo and clinical study. Proc Am Soc Clin Oncol 1999; 18:187 a (abstr 718).
10. Mountain C.F., Dresler C.M. Regional lymph node classification for lung cancer staging. Chest. 111:1997;1718-1723
11. Shimoyama M. The Japanese edition of the National Cancer Institute-Common Toxicity Criteria. Gan to Kagaku Ryoho. 26:1999;1084-1144. (in Japanese)
12. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92:2000;205-216
13. Kurita A., Kaneda N. High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT. J. Chromatogr. 724:1999;335-344
14. Rosen P, Schaaf LJ, Knuth DW, Parson M, Kadib L, Rosen L, et al. Phase I and pharmacokinetic trial of CPT-11 and paclitaxel in patients with advanced cancers. Proc Am Soc Clin Oncol 1999;18:177a (abstr 679).
15. Murren J.R., Peccerillo K., DiStasio S.A., Li X., Leffert J.J., Pizzorno G., et al. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer. Cancer Chemother. Pharmacol. 46:2000;43-50
16. Kelly K., Crowley J., Bunn P.A. Jr., Presant C.A., Grevstad P.K., Moinpour C.M., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol. 19:2001;3210-3218
17. Haaz M.C., Rivory L., Riché C., Vernillet L., Robert J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res. 58:1998;468-472
18. Kumar G.N., Walle U.K., Walle T. Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. J. Pharmacol. Exp. Ther. 268:1994;1160-1165
19. Kawato Y., Aonuma M., Hirota Y., Kuga H., Sato K. Intracellular roles of SN-38, a metabolite of camptothecin derivative CPT-11 in the antitumor effect of CPT-11. Cancer Res. 51:1991;4187-4191
20. Rahman A., Korzekwa K.R., Grogan J., Gomzalez F.J., Harris J.W. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54:1994;5543-5546
21. Kano Y., Akutsu M., Tsunoda S., Mori K., Suzuki K., Adachi K. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines. Cancer Chemother. Pharmacol. 42:1998;91-98
22. Debernardis D., Cimoli G., Parodi S., Russo P. Interactions between taxol and camptothecin. Anticancer Drugs. 7:1996;531-534
23. Garcia-Carbonero R., Supko J.G. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res. 8:2002;641-661